



ATTD 2026

March 11-15, 2026; Barcelona, Spain + Virtual; Resource Hub - Draft

Welcome to our resource hub for ATTD 2026! This is a one-stop-shop for all your ATTD 2026 needs. We will be updating the resource hub daily, so check back in for the latest on this fantastic meeting.

Table of Contents

[Day-of Conference Reports](#)

[Diabetes Technology Highlights](#)

[Diabetes Therapy Highlights](#)

[Big Picture Highlights](#)

Day-of Conference Reports

- [Day #1 Highlights](#)
- [Day #2 Highlights](#)
- [Day #3 Highlights](#)
- [Day #4 Highlights](#)

Diabetes Technology Highlights

1. [Opening Lecture on human-AI collaboration in diabetes](#): Prof. Boris Kovatchev on developing AI digital twins
2. [Insulet: Drs. Trang Ly and Martin de Bock on “Helping diabetes disappear”](#): Fully closed-loop AID for T2D and beyond
3. [Abbott: Experts highlight continuous ketone monitoring](#) and its applications to dual glucose-ketone sensing (DGK) for the prevention of DKA
4. [Roche: Profs. Bogdan Timar and Guido Freckmann](#) on moving from trend-following to proactive intervention with CGM
5. [Expanding the role of CGM](#) in diabetes detection and early diabetes management
6. [Tandem: Features, early user data](#), and glycemic strategies with Tandem Mobi
7. [Prof. Emma Wilmot addresses evidence](#) and access for CGM in T2D
8. [Inpatient diabetes management](#): Emerging CGM evidence highlights improvements in glycemic outcomes in the hospital
9. [FreeDM2 trial: FreeStyle Libre 3 improves A1c and TIR](#) compared to BGM in adults with T2D on basal insulin and SGLT-2 inhibitors or incretins
10. [Using AID to overcome clinical inertia](#) in basal insulin dosing for T2D
11. [Dr. Viral Shah on CGM for prediabetes](#): Staging, diagnosis, and potential therapeutic options
12. [Fully closed-loop AID](#): Dr. Rayhan Lal discusses future challenges and considerations
13. [CGM use in people without diabetes](#): New metrics for phenotyping, Time in Tight Range, and foundation models for glucose
14. [Real-world performance of the Instinct sensor](#) with the MiniMed 780G AID system
15. [From hybrid to fully closed-loop](#): Dr. Marc Breton discusses UVA’s AIDANET AI-driven AID system and early

trial results

16. [dQ&A presents data on DKA awareness](#) and ketone testing behavior of adults with T1D
17. [Dexcom unveils Smart Basal dosing](#), extended high glucose alerts, and a new sensor patch in dynamic symposium
18. [Toward hands-off diabetes care](#): MiniMed unveils the Vivera fully closed-loop algorithm
19. [Debate](#): Should A1c or CGM be the gold standard for glycemic management?
20. [mylife Diabetes Care](#): Evidence and clinical pearls for personalization AID with CamAPS FX
21. [CGM metrics as predictors of vascular risk](#): Insights from Virtual DCCT and real-world evidence
22. [Dr. Ahmad Haider takes a first pass at recommendations](#) for continuous ketone level targets for people with T1D on SGLT-2 inhibitors
23. [A preview of continuous ketone monitoring data from Abbott](#): Drs. Ketan Dhatariya and Rich Bergenstal highlight much to be learned
24. [From prediabetes to basal insulin](#): Early CGM use to transform T2D care
25. [Integrating wearable technology](#) into adult diabetes care
26. [An opportunity for a “generational leap”](#): Use of ultra-rapid acting insulin in AID systems
27. [Interception and education: Prof. Stephanie Amiel on the CLEAR trial and HARPdoc](#) for improving hypoglycemia awareness in T1D
28. [Omnipod 5 in the real world](#): Evidence in infants and toddlers, those with very low insulin requirements, and those using optimal settings
29. [Sequel MedTech shares real-world data from the first twiist users \(n=274\)](#), with mean TIR of 77% and TBR of 2.9%
30. [MiniMed presents three studies comparing Simpleria Sync and Instinct](#), studying low glucose alerts, and exploring missed meal boluses
31. [Results from Italian study of adolescents](#) with T1D switching between Guardian 4 and Simpleria Sync sensors
32. [New Eversense 365 CGM real-world data \(n=5,000+\) shows up to 72% TIR](#); preliminary data from twiist AID integration shows 77% TIR
33. [CGM use is not effective for healthy lifestyle modification](#) in people without diabetes
34. [Diabetic ketoacidosis in T1D and T2D](#): Epidemiology, provider perspectives, and the promising role of technology
35. [Dr. David Klonoff on the glycemic risk index](#) and its clinical and research benefits
36. [MiniMed symposium spotlights simplified onboarding for 780G](#), future innovation pipeline, and MiniMed Go
37. [Clinical implications of extended-wear infusion sites](#) in insulin pump therapy
38. [Biolineq’s intradermal glucose monitor](#): Feasibility data supports longer wear time
39. [Accuracy of a novel, real-time CGM in adults with diabetes](#): A preliminary analysis
40. [India D-Tech session takes on diabetes care gaps](#) with clinical decision support and practical CGM use
41. [Use of CGM in gestational diabetes](#): CGM metrics show differences in GDM status well before OGTT
42. [Glycemic outcomes associated with switching from intermittently-scanned to real-time CGM](#) in people with T2D on insulin
43. [dQ&A study examines the impact of AID systems](#) on diabetes burden and user satisfaction
44. [First phase 1 data for PharmaSens’ combined insulin patch pump and CGM](#); second clinical trial planned for 2Q26
45. [The future of smart pens: Market growth, real-world uptake, and pediatric use](#)
46. ***NEW*** [Feasibility of decentralized clinical trials](#) in diabetes management studies

- 47. [***NEW*** Dr. Jennifer Sherr on strategies to optimize outcomes with AID](#)
- 48. [***NEW*** Large real-world analysis finds significant reductions in MACE and mortality with CGM use in T1D](#)

Diabetes Therapy Highlights

- 1. [Lilly: Profs. Chantal Mathieu and Harpreet Bajaj on the potential for once-weekly insulins](#), including in combination with GLP-1 RAs, metformin, and AID system
- 2. [Vertex: Symposium reflects on the T1D landscape](#) and highlights the next chapter with islet cell therapy
- 3. [Dr. Anastasia Albanese-O'Neill on building a global consensus for early-stage T1D screening](#) and monitoring at the general population level
- 4. [EDENT1FI screens over 100,000 children](#) in Europe for early stage T1D
- 5. [Sanofi's symposium highlights the future of T1D screening](#) and disease-modifying therapies
- 6. [SURPASS-EARLY: Early initiation of tirzepatide for T2D](#) improves glycemic and cardiovascular health
- 7. [Dr. Jeremy Pettus introduces a novel gene therapy for T1D](#), KRIYA-839, which will enter the first-in-human phase 1/2 trial in 2026
- 8. [Post-hoc analysis of the QWINT program](#) finds comparable hypoglycemia duration between once-weekly efsitora alfa and daily basal insulin
- 9. [Dr. Viswanathan Mohan on the distinction between IFG and IGT](#) in diabetes prevention
- 10. [Adjust T1D study of GLP-1 RA use in adults with T1D and obesity](#) shows significant reductions in cardiovascular outcomes and disease risk
- 11. [Real-world evidence of reclassification to T1D](#) following misdiagnosis
- 12. [Dr. Satish Garg on the adjunctive use of incretins in T1D and obesity](#): Recommendations from an upcoming consensus report
- 13. [Interim results for Diamyd's phase 3 DIAGNODE-3 results for retogatein](#) in stage 3 T1D expected by end of month
- 14. [Clinical pearls on once-weekly insulin use](#) in insulin-naïve and insulin-experienced people with T2D
- 15. [T1D screening and monitoring](#): IDF Europe's international consensus on for early-stage T1D now published
- 16. [Lilly symposium](#): SURPASS-EARLY trial underscores the potential to alter T2D progression with early tirzepatide treatment
- 17. [Eight years of normoglycemia in preclinical T1D models of KRIYA-839](#): one administration designed to last a patient's lifetime
- 18. [Immediate, intensive glycemic management for T2D](#): An argument for early insulin initiation
- 19. [Dr. Jay Skyler and his "mission to eradicate T1D"](#)
- 20. [Saliva-based screening: T1D Scout's program](#) to expand large-scale screening by identifying high-risk populations
- 21. [Obesity in T1D](#): Etiology and GLP-1 RAs as a promising therapy

Big Picture Highlights

- 1. [Opening Ceremony](#) highlights ATTD's global reach
- 2. [ATTD 2026 exhibit hall brings together 80+ companies](#) highlighting the latest in diabetes technologies and therapies
- 3. [Breakthrough T1D to train interventional diabetologists and endocrinologists](#) through US certificate program and joint course with ATTD
- 4. [Delaying the onset of T1D](#): Screening and treatment options

5. [Bridging the gap between population screening](#) and initiation of immunotherapy
6. [Exercise and T1D](#): Physiological differences, clinical trials, real-world evidence, and continuous lactate monitoring
7. [IDF Europe symposium](#) focuses on diabetes detection, treatments, and cures
8. [Beyond glycemia](#): Addressing overweight and obesity in T1D
9. [Early-onset T2D in pregnancy](#): Prof. Helen Murphy highlights rising prevalence and urgent need for stronger preconception care
10. [C-peptide as a marker for functional beta cell mass](#): Pushing the momentum for disease-modifying T1D treatment
11. [Cardiovascular disease in T1D](#): Pathophysiology, pharmacotherapy, and exercise
12. [Prof. Chantal Mathieu receives ATTD Breakthrough Award](#) during closing ceremony